nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—breast cancer—bone cancer	0.47	0.519	CtDrD
Goserelin—prostate cancer—bone cancer	0.436	0.481	CtDrD
Goserelin—LHCGR—Arf6 signaling events—GNA11—bone cancer	0.00133	0.127	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—CDK4—bone cancer	0.000805	0.0769	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—MET—bone cancer	0.000749	0.0715	CbGpPWpGaD
Goserelin—GNRHR—GPCRs, Other—GRM1—bone cancer	0.000645	0.0616	CbGpPWpGaD
Goserelin—GNRHR—GPCRs, Other—SMO—bone cancer	0.000454	0.0434	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—EGFR—bone cancer	0.000379	0.0362	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—GRM1—bone cancer	0.000362	0.0346	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000324	0.0309	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—GRM4—bone cancer	0.000315	0.0301	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—GRM1—bone cancer	0.000273	0.0261	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—GNA11—bone cancer	0.000233	0.0223	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—GRM4—bone cancer	0.000211	0.0201	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000209	0.0199	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—SMO—bone cancer	0.000192	0.0184	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—GRM1—bone cancer	0.000183	0.0175	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—RGS1—bone cancer	0.000178	0.017	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—GRM4—bone cancer	0.000178	0.017	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—GRM4—bone cancer	0.000162	0.0154	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—RGS1—bone cancer	0.000162	0.0154	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—GRM1—bone cancer	0.000154	0.0147	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—GRM1—bone cancer	0.00014	0.0134	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—SMO—bone cancer	0.000129	0.0123	CbGpPWpGaD
Goserelin—Haematuria—Methotrexate—bone cancer	0.000121	0.00143	CcSEcCtD
Goserelin—Hyperglycaemia—Epirubicin—bone cancer	0.00012	0.00142	CcSEcCtD
Goserelin—Angina pectoris—Doxorubicin—bone cancer	0.00012	0.00142	CcSEcCtD
Goserelin—Epistaxis—Methotrexate—bone cancer	0.00012	0.00142	CcSEcCtD
Goserelin—Pneumonia—Epirubicin—bone cancer	0.000119	0.00141	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—GRM4—bone cancer	0.000119	0.0114	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—RGS1—bone cancer	0.000119	0.0114	CbGpPWpGaD
Goserelin—Drowsiness—Epirubicin—bone cancer	0.000119	0.00141	CcSEcCtD
Goserelin—Bronchitis—Doxorubicin—bone cancer	0.000118	0.0014	CcSEcCtD
Goserelin—Renal failure—Epirubicin—bone cancer	0.000117	0.00138	CcSEcCtD
Goserelin—Body temperature increased—Cisplatin—bone cancer	0.000116	0.00138	CcSEcCtD
Goserelin—Jaundice—Epirubicin—bone cancer	0.000116	0.00137	CcSEcCtD
Goserelin—Urinary tract infection—Epirubicin—bone cancer	0.000115	0.00137	CcSEcCtD
Goserelin—Dysuria—Doxorubicin—bone cancer	0.000115	0.00137	CcSEcCtD
Goserelin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000114	0.00136	CcSEcCtD
Goserelin—Haemoglobin—Methotrexate—bone cancer	0.000114	0.00136	CcSEcCtD
Goserelin—Haemorrhage—Methotrexate—bone cancer	0.000114	0.00135	CcSEcCtD
Goserelin—Hepatitis—Methotrexate—bone cancer	0.000114	0.00135	CcSEcCtD
Goserelin—Sweating—Epirubicin—bone cancer	0.000114	0.00135	CcSEcCtD
Goserelin—Pollakiuria—Doxorubicin—bone cancer	0.000114	0.00135	CcSEcCtD
Goserelin—Haematuria—Epirubicin—bone cancer	0.000113	0.00134	CcSEcCtD
Goserelin—Pharyngitis—Methotrexate—bone cancer	0.000113	0.00134	CcSEcCtD
Goserelin—Urinary tract disorder—Methotrexate—bone cancer	0.000112	0.00133	CcSEcCtD
Goserelin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000112	0.00133	CcSEcCtD
Goserelin—Weight increased—Doxorubicin—bone cancer	0.000112	0.00133	CcSEcCtD
Goserelin—Epistaxis—Epirubicin—bone cancer	0.000112	0.00133	CcSEcCtD
Goserelin—Urethral disorder—Methotrexate—bone cancer	0.000112	0.00132	CcSEcCtD
Goserelin—Sinusitis—Epirubicin—bone cancer	0.000111	0.00132	CcSEcCtD
Goserelin—Hyperglycaemia—Doxorubicin—bone cancer	0.000111	0.00132	CcSEcCtD
Goserelin—Pneumonia—Doxorubicin—bone cancer	0.00011	0.00131	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—bone cancer	0.00011	0.0013	CcSEcCtD
Goserelin—Hypersensitivity—Cisplatin—bone cancer	0.000109	0.00129	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—GRM4—bone cancer	0.000108	0.0103	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—RGS1—bone cancer	0.000108	0.0103	CbGpPWpGaD
Goserelin—Renal failure—Doxorubicin—bone cancer	0.000108	0.00128	CcSEcCtD
Goserelin—Haemoglobin—Epirubicin—bone cancer	0.000107	0.00127	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—bone cancer	0.000107	0.00127	CcSEcCtD
Goserelin—Rhinitis—Epirubicin—bone cancer	0.000107	0.00127	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—bone cancer	0.000107	0.00127	CcSEcCtD
Goserelin—Haemorrhage—Epirubicin—bone cancer	0.000107	0.00126	CcSEcCtD
Goserelin—Hepatitis—Epirubicin—bone cancer	0.000107	0.00126	CcSEcCtD
Goserelin—Eye disorder—Methotrexate—bone cancer	0.000106	0.00126	CcSEcCtD
Goserelin—Asthenia—Cisplatin—bone cancer	0.000106	0.00125	CcSEcCtD
Goserelin—Pharyngitis—Epirubicin—bone cancer	0.000106	0.00125	CcSEcCtD
Goserelin—Cardiac disorder—Methotrexate—bone cancer	0.000106	0.00125	CcSEcCtD
Goserelin—Sweating—Doxorubicin—bone cancer	0.000105	0.00125	CcSEcCtD
Goserelin—Urinary tract disorder—Epirubicin—bone cancer	0.000105	0.00125	CcSEcCtD
Goserelin—Oedema peripheral—Epirubicin—bone cancer	0.000105	0.00124	CcSEcCtD
Goserelin—Haematuria—Doxorubicin—bone cancer	0.000105	0.00124	CcSEcCtD
Goserelin—Urethral disorder—Epirubicin—bone cancer	0.000104	0.00124	CcSEcCtD
Goserelin—Epistaxis—Doxorubicin—bone cancer	0.000104	0.00123	CcSEcCtD
Goserelin—Angiopathy—Methotrexate—bone cancer	0.000103	0.00122	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—GRM1—bone cancer	0.000103	0.00986	CbGpPWpGaD
Goserelin—Sinusitis—Doxorubicin—bone cancer	0.000103	0.00122	CcSEcCtD
Goserelin—Immune system disorder—Methotrexate—bone cancer	0.000103	0.00122	CcSEcCtD
Goserelin—Chills—Methotrexate—bone cancer	0.000102	0.00121	CcSEcCtD
Goserelin—Diarrhoea—Cisplatin—bone cancer	0.000101	0.0012	CcSEcCtD
Goserelin—Alopecia—Methotrexate—bone cancer	0.000101	0.00119	CcSEcCtD
Goserelin—Mental disorder—Methotrexate—bone cancer	9.97e-05	0.00118	CcSEcCtD
Goserelin—Eye disorder—Epirubicin—bone cancer	9.95e-05	0.00118	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—GNA11—bone cancer	9.94e-05	0.00949	CbGpPWpGaD
Goserelin—Erythema—Methotrexate—bone cancer	9.91e-05	0.00117	CcSEcCtD
Goserelin—Malnutrition—Methotrexate—bone cancer	9.91e-05	0.00117	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—bone cancer	9.91e-05	0.00117	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—bone cancer	9.89e-05	0.00117	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—bone cancer	9.88e-05	0.00117	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—SMO—bone cancer	9.87e-05	0.00943	CbGpPWpGaD
Goserelin—Hepatitis—Doxorubicin—bone cancer	9.86e-05	0.00117	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—bone cancer	9.86e-05	0.00117	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—bone cancer	9.78e-05	0.00116	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—bone cancer	9.73e-05	0.00115	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—bone cancer	9.71e-05	0.00115	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—bone cancer	9.66e-05	0.00115	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—bone cancer	9.66e-05	0.00115	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—bone cancer	9.62e-05	0.00114	CcSEcCtD
Goserelin—Back pain—Methotrexate—bone cancer	9.58e-05	0.00114	CcSEcCtD
Goserelin—Chills—Epirubicin—bone cancer	9.56e-05	0.00113	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—GRM4—bone cancer	9.54e-05	0.00911	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RGS1—bone cancer	9.54e-05	0.00911	CbGpPWpGaD
Goserelin—Arrhythmia—Epirubicin—bone cancer	9.52e-05	0.00113	CcSEcCtD
Goserelin—Alopecia—Epirubicin—bone cancer	9.41e-05	0.00112	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—GRM1—bone cancer	9.38e-05	0.00896	CbGpPWpGaD
Goserelin—Vomiting—Cisplatin—bone cancer	9.37e-05	0.00111	CcSEcCtD
Goserelin—Vision blurred—Methotrexate—bone cancer	9.34e-05	0.00111	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—bone cancer	9.33e-05	0.00111	CcSEcCtD
Goserelin—Rash—Cisplatin—bone cancer	9.29e-05	0.0011	CcSEcCtD
Goserelin—Dermatitis—Cisplatin—bone cancer	9.28e-05	0.0011	CcSEcCtD
Goserelin—Erythema—Epirubicin—bone cancer	9.27e-05	0.0011	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—bone cancer	9.27e-05	0.0011	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—bone cancer	9.21e-05	0.00109	CcSEcCtD
Goserelin—Ill-defined disorder—Methotrexate—bone cancer	9.19e-05	0.00109	CcSEcCtD
Goserelin—Anaemia—Methotrexate—bone cancer	9.16e-05	0.00109	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—bone cancer	9.15e-05	0.00108	CcSEcCtD
Goserelin—Flatulence—Epirubicin—bone cancer	9.14e-05	0.00108	CcSEcCtD
Goserelin—Tension—Epirubicin—bone cancer	9.1e-05	0.00108	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—GNA11—bone cancer	9.03e-05	0.00862	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—IL3—bone cancer	9.01e-05	0.00861	CbGpPWpGaD
Goserelin—Nervousness—Epirubicin—bone cancer	9.01e-05	0.00107	CcSEcCtD
Goserelin—Back pain—Epirubicin—bone cancer	8.97e-05	0.00106	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—bone cancer	8.94e-05	0.00106	CcSEcCtD
Goserelin—Malaise—Methotrexate—bone cancer	8.94e-05	0.00106	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—bone cancer	8.91e-05	0.00106	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—bone cancer	8.9e-05	0.00106	CcSEcCtD
Goserelin—Leukopenia—Methotrexate—bone cancer	8.87e-05	0.00105	CcSEcCtD
Goserelin—Chills—Doxorubicin—bone cancer	8.84e-05	0.00105	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—bone cancer	8.8e-05	0.00104	CcSEcCtD
Goserelin—Nausea—Cisplatin—bone cancer	8.75e-05	0.00104	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—bone cancer	8.74e-05	0.00104	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—bone cancer	8.71e-05	0.00103	CcSEcCtD
Goserelin—Cough—Methotrexate—bone cancer	8.65e-05	0.00103	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—bone cancer	8.63e-05	0.00102	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—bone cancer	8.6e-05	0.00102	CcSEcCtD
Goserelin—Convulsion—Methotrexate—bone cancer	8.58e-05	0.00102	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—bone cancer	8.58e-05	0.00102	CcSEcCtD
Goserelin—Erythema—Doxorubicin—bone cancer	8.58e-05	0.00102	CcSEcCtD
Goserelin—Anaemia—Epirubicin—bone cancer	8.57e-05	0.00102	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—bone cancer	8.45e-05	0.001	CcSEcCtD
Goserelin—Arthralgia—Methotrexate—bone cancer	8.44e-05	0.001	CcSEcCtD
Goserelin—Myalgia—Methotrexate—bone cancer	8.44e-05	0.001	CcSEcCtD
Goserelin—Chest pain—Methotrexate—bone cancer	8.44e-05	0.001	CcSEcCtD
Goserelin—Tension—Doxorubicin—bone cancer	8.42e-05	0.000998	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	8.38e-05	0.000993	CcSEcCtD
Goserelin—Malaise—Epirubicin—bone cancer	8.36e-05	0.000991	CcSEcCtD
Goserelin—Discomfort—Methotrexate—bone cancer	8.33e-05	0.000988	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—bone cancer	8.33e-05	0.000988	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—bone cancer	8.3e-05	0.000984	CcSEcCtD
Goserelin—Back pain—Doxorubicin—bone cancer	8.3e-05	0.000984	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—GRM1—bone cancer	8.27e-05	0.0079	CbGpPWpGaD
Goserelin—Muscle spasms—Doxorubicin—bone cancer	8.25e-05	0.000978	CcSEcCtD
Goserelin—Palpitations—Epirubicin—bone cancer	8.19e-05	0.000971	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—IL3—bone cancer	8.18e-05	0.00782	CbGpPWpGaD
Goserelin—Confusional state—Methotrexate—bone cancer	8.15e-05	0.000967	CcSEcCtD
Goserelin—Cough—Epirubicin—bone cancer	8.09e-05	0.000959	CcSEcCtD
Goserelin—Anaphylactic shock—Methotrexate—bone cancer	8.09e-05	0.000959	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—bone cancer	8.09e-05	0.000959	CcSEcCtD
Goserelin—Convulsion—Epirubicin—bone cancer	8.03e-05	0.000952	CcSEcCtD
Goserelin—Infection—Methotrexate—bone cancer	8.03e-05	0.000952	CcSEcCtD
Goserelin—Hypertension—Epirubicin—bone cancer	8.01e-05	0.000949	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—bone cancer	7.96e-05	0.000944	CcSEcCtD
Goserelin—Nervous system disorder—Methotrexate—bone cancer	7.93e-05	0.00094	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—bone cancer	7.93e-05	0.00094	CcSEcCtD
Goserelin—Thrombocytopenia—Methotrexate—bone cancer	7.92e-05	0.000939	CcSEcCtD
Goserelin—Myalgia—Epirubicin—bone cancer	7.89e-05	0.000936	CcSEcCtD
Goserelin—Chest pain—Epirubicin—bone cancer	7.89e-05	0.000936	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—bone cancer	7.89e-05	0.000936	CcSEcCtD
Goserelin—Anxiety—Epirubicin—bone cancer	7.87e-05	0.000933	CcSEcCtD
Goserelin—Skin disorder—Methotrexate—bone cancer	7.85e-05	0.000931	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	7.84e-05	0.000929	CcSEcCtD
Goserelin—Hyperhidrosis—Methotrexate—bone cancer	7.82e-05	0.000927	CcSEcCtD
Goserelin—Discomfort—Epirubicin—bone cancer	7.8e-05	0.000925	CcSEcCtD
Goserelin—Malaise—Doxorubicin—bone cancer	7.74e-05	0.000917	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—bone cancer	7.72e-05	0.000915	CcSEcCtD
Goserelin—Anorexia—Methotrexate—bone cancer	7.71e-05	0.000914	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—bone cancer	7.68e-05	0.00091	CcSEcCtD
Goserelin—Confusional state—Epirubicin—bone cancer	7.63e-05	0.000905	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—bone cancer	7.58e-05	0.000899	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—bone cancer	7.57e-05	0.000897	CcSEcCtD
Goserelin—Oedema—Epirubicin—bone cancer	7.57e-05	0.000897	CcSEcCtD
Goserelin—Hypotension—Methotrexate—bone cancer	7.56e-05	0.000896	CcSEcCtD
Goserelin—Infection—Epirubicin—bone cancer	7.52e-05	0.000891	CcSEcCtD
Goserelin—Cough—Doxorubicin—bone cancer	7.49e-05	0.000888	CcSEcCtD
Goserelin—Shock—Epirubicin—bone cancer	7.45e-05	0.000883	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—bone cancer	7.43e-05	0.000881	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—bone cancer	7.42e-05	0.00088	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—bone cancer	7.41e-05	0.000878	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—bone cancer	7.41e-05	0.000878	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—bone cancer	7.39e-05	0.000876	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Methotrexate—bone cancer	7.37e-05	0.000873	CcSEcCtD
Goserelin—Skin disorder—Epirubicin—bone cancer	7.35e-05	0.000871	CcSEcCtD
Goserelin—Hyperhidrosis—Epirubicin—bone cancer	7.32e-05	0.000867	CcSEcCtD
Goserelin—Insomnia—Methotrexate—bone cancer	7.31e-05	0.000867	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—bone cancer	7.3e-05	0.000866	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—bone cancer	7.3e-05	0.000866	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—bone cancer	7.3e-05	0.000866	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—bone cancer	7.28e-05	0.000863	CcSEcCtD
Goserelin—Paraesthesia—Methotrexate—bone cancer	7.26e-05	0.000861	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	7.25e-05	0.00086	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—bone cancer	7.22e-05	0.000856	CcSEcCtD
Goserelin—Anorexia—Epirubicin—bone cancer	7.21e-05	0.000855	CcSEcCtD
Goserelin—Dyspnoea—Methotrexate—bone cancer	7.21e-05	0.000855	CcSEcCtD
Goserelin—Somnolence—Methotrexate—bone cancer	7.19e-05	0.000852	CcSEcCtD
Goserelin—Dry mouth—Doxorubicin—bone cancer	7.14e-05	0.000847	CcSEcCtD
Goserelin—Dyspepsia—Methotrexate—bone cancer	7.12e-05	0.000844	CcSEcCtD
Goserelin—Hypotension—Epirubicin—bone cancer	7.07e-05	0.000838	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—bone cancer	7.06e-05	0.000837	CcSEcCtD
Goserelin—Decreased appetite—Methotrexate—bone cancer	7.03e-05	0.000833	CcSEcCtD
Goserelin—Oedema—Doxorubicin—bone cancer	7e-05	0.00083	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—bone cancer	7e-05	0.00083	CcSEcCtD
Goserelin—Fatigue—Methotrexate—bone cancer	6.97e-05	0.000827	CcSEcCtD
Goserelin—Infection—Doxorubicin—bone cancer	6.96e-05	0.000825	CcSEcCtD
Goserelin—Pain—Methotrexate—bone cancer	6.92e-05	0.00082	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—bone cancer	6.89e-05	0.000817	CcSEcCtD
Goserelin—Shock—Doxorubicin—bone cancer	6.89e-05	0.000817	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—bone cancer	6.87e-05	0.000814	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—bone cancer	6.86e-05	0.000813	CcSEcCtD
Goserelin—Insomnia—Epirubicin—bone cancer	6.84e-05	0.000811	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—bone cancer	6.83e-05	0.00081	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—bone cancer	6.8e-05	0.000806	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—bone cancer	6.8e-05	0.000806	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—bone cancer	6.77e-05	0.000802	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—bone cancer	6.75e-05	0.0008	CcSEcCtD
Goserelin—Somnolence—Epirubicin—bone cancer	6.73e-05	0.000798	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—bone cancer	6.67e-05	0.000791	CcSEcCtD
Goserelin—Feeling abnormal—Methotrexate—bone cancer	6.66e-05	0.00079	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—bone cancer	6.66e-05	0.00079	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—GNA11—bone cancer	6.65e-05	0.00636	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Methotrexate—bone cancer	6.61e-05	0.000784	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—SMO—bone cancer	6.61e-05	0.00631	CbGpPWpGaD
Goserelin—Decreased appetite—Epirubicin—bone cancer	6.58e-05	0.00078	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—bone cancer	6.54e-05	0.000776	CcSEcCtD
Goserelin—Fatigue—Epirubicin—bone cancer	6.52e-05	0.000773	CcSEcCtD
Goserelin—Constipation—Epirubicin—bone cancer	6.47e-05	0.000767	CcSEcCtD
Goserelin—Pain—Epirubicin—bone cancer	6.47e-05	0.000767	CcSEcCtD
Goserelin—Urticaria—Methotrexate—bone cancer	6.42e-05	0.000762	CcSEcCtD
Goserelin—Body temperature increased—Methotrexate—bone cancer	6.39e-05	0.000758	CcSEcCtD
Goserelin—Abdominal pain—Methotrexate—bone cancer	6.39e-05	0.000758	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—GRM4—bone cancer	6.39e-05	0.0061	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RGS1—bone cancer	6.39e-05	0.0061	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.38e-05	0.000756	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—bone cancer	6.33e-05	0.000751	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—bone cancer	6.29e-05	0.000745	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—bone cancer	6.24e-05	0.00074	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—bone cancer	6.24e-05	0.000739	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—bone cancer	6.22e-05	0.000738	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—bone cancer	6.19e-05	0.000734	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—bone cancer	6.16e-05	0.000731	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—bone cancer	6.09e-05	0.000722	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—GNA11—bone cancer	6.04e-05	0.00577	CbGpPWpGaD
Goserelin—Fatigue—Doxorubicin—bone cancer	6.04e-05	0.000716	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—IL3—bone cancer	6.03e-05	0.00576	CbGpPWpGaD
Goserelin—Urticaria—Epirubicin—bone cancer	6.01e-05	0.000713	CcSEcCtD
Goserelin—Constipation—Doxorubicin—bone cancer	5.99e-05	0.00071	CcSEcCtD
Goserelin—Pain—Doxorubicin—bone cancer	5.99e-05	0.00071	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—bone cancer	5.98e-05	0.000709	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—bone cancer	5.98e-05	0.000709	CcSEcCtD
Goserelin—Hypersensitivity—Methotrexate—bone cancer	5.96e-05	0.000706	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	5.95e-05	0.00568	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SMO—bone cancer	5.83e-05	0.00557	CbGpPWpGaD
Goserelin—Asthenia—Methotrexate—bone cancer	5.8e-05	0.000688	CcSEcCtD
Goserelin—Feeling abnormal—Doxorubicin—bone cancer	5.77e-05	0.000684	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—bone cancer	5.73e-05	0.000679	CcSEcCtD
Goserelin—Pruritus—Methotrexate—bone cancer	5.72e-05	0.000678	CcSEcCtD
Goserelin—Hypersensitivity—Epirubicin—bone cancer	5.58e-05	0.000661	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—bone cancer	5.56e-05	0.000659	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—GRM1—bone cancer	5.54e-05	0.00529	CbGpPWpGaD
Goserelin—Body temperature increased—Doxorubicin—bone cancer	5.54e-05	0.000656	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—bone cancer	5.54e-05	0.000656	CcSEcCtD
Goserelin—Diarrhoea—Methotrexate—bone cancer	5.53e-05	0.000656	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL3—bone cancer	5.48e-05	0.00523	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—bone cancer	5.43e-05	0.000644	CcSEcCtD
Goserelin—Pruritus—Epirubicin—bone cancer	5.35e-05	0.000635	CcSEcCtD
Goserelin—Dizziness—Methotrexate—bone cancer	5.35e-05	0.000634	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—GNA11—bone cancer	5.33e-05	0.00509	CbGpPWpGaD
Goserelin—Diarrhoea—Epirubicin—bone cancer	5.18e-05	0.000614	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—bone cancer	5.16e-05	0.000612	CcSEcCtD
Goserelin—Vomiting—Methotrexate—bone cancer	5.14e-05	0.00061	CcSEcCtD
Goserelin—Rash—Methotrexate—bone cancer	5.1e-05	0.000604	CcSEcCtD
Goserelin—Dermatitis—Methotrexate—bone cancer	5.09e-05	0.000604	CcSEcCtD
Goserelin—Headache—Methotrexate—bone cancer	5.07e-05	0.000601	CcSEcCtD
Goserelin—Asthenia—Doxorubicin—bone cancer	5.02e-05	0.000596	CcSEcCtD
Goserelin—Dizziness—Epirubicin—bone cancer	5e-05	0.000593	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—ATF1—bone cancer	4.96e-05	0.00473	CbGpPWpGaD
Goserelin—Pruritus—Doxorubicin—bone cancer	4.95e-05	0.000587	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL3—bone cancer	4.83e-05	0.00462	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—bone cancer	4.81e-05	0.00057	CcSEcCtD
Goserelin—Nausea—Methotrexate—bone cancer	4.8e-05	0.000569	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—bone cancer	4.79e-05	0.000568	CcSEcCtD
Goserelin—Rash—Epirubicin—bone cancer	4.77e-05	0.000566	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—bone cancer	4.77e-05	0.000565	CcSEcCtD
Goserelin—Headache—Epirubicin—bone cancer	4.74e-05	0.000562	CcSEcCtD
Goserelin—Dizziness—Doxorubicin—bone cancer	4.63e-05	0.000549	CcSEcCtD
Goserelin—Nausea—Epirubicin—bone cancer	4.5e-05	0.000533	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—bone cancer	4.45e-05	0.000528	CcSEcCtD
Goserelin—Rash—Doxorubicin—bone cancer	4.41e-05	0.000523	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—bone cancer	4.41e-05	0.000523	CcSEcCtD
Goserelin—Headache—Doxorubicin—bone cancer	4.39e-05	0.00052	CcSEcCtD
Goserelin—Nausea—Doxorubicin—bone cancer	4.16e-05	0.000493	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—TGFBR2—bone cancer	4.13e-05	0.00395	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SMO—bone cancer	3.9e-05	0.00373	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IGF1R—bone cancer	3.89e-05	0.00372	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GNA11—bone cancer	3.57e-05	0.00341	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ATF1—bone cancer	3.32e-05	0.00317	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL3—bone cancer	3.24e-05	0.00309	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KIT—bone cancer	2.82e-05	0.00269	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFBR2—bone cancer	2.77e-05	0.00264	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BRAF—bone cancer	2.65e-05	0.00253	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IGF1R—bone cancer	2.6e-05	0.00249	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—EGFR—bone cancer	2.57e-05	0.00245	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MDM2—bone cancer	2.22e-05	0.00212	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUN—bone cancer	1.93e-05	0.00184	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KIT—bone cancer	1.89e-05	0.0018	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MMP9—bone cancer	1.88e-05	0.00179	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BRAF—bone cancer	1.78e-05	0.0017	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—EGFR—bone cancer	1.72e-05	0.00164	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGFR—bone cancer	1.52e-05	0.00145	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MDM2—bone cancer	1.49e-05	0.00142	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JUN—bone cancer	1.29e-05	0.00123	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—bone cancer	1.27e-05	0.00122	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP9—bone cancer	1.26e-05	0.0012	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—bone cancer	1.02e-05	0.000971	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—bone cancer	8.53e-06	0.000815	CbGpPWpGaD
